Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term ExtensionECCO'24 Stockholm 2024
Longitudinal gut microbiome dynamics in relation to disease flares in Inflammatory Bowel Disease, pilot data from the IBD-Tracker studyECCO'24 Stockholm 2024
MB310: From Clinical FMT to a Phase 1 Study with a Defined, Orally Administered Live Bacterial Therapeutic for Mild Moderate Ulcerative ColitisECCO'24 Stockholm 2024
Mechanistic insights on the role of ultra processed foods as a trigger/fuel for IBDECCO'24 Stockholm 2024
Mesenchymal stem cell therapy for refractory Crohn’s perianal fistulas: a case seriesECCO'24 Stockholm 2024
Metagenomic and metabolomic profiles in IBD: understanding microbial and metabolic shifts from a large deeply phenotyped cohortECCO'24 Stockholm 2024
Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trialECCO'24 Stockholm 2024
Models for predicting Crohn Disease (CD) exacerbation using serum and fecal metabolomicsECCO'24 Stockholm 2024
Monitoring disease activity by intestinal ultrasound predicts biologic treatment persistence in patients with Inflammatory Bowel DiseaseECCO'24 Stockholm 2024
Mortality in Pediatric-onset Immune-Mediated Inflammatory Disease – A Nationwide Study.ECCO'24 Stockholm 2024
Mucosal single-cell profiling of Crohn's-like disease of the pouch reveal unique pathogenesis and therapeutic targetsECCO'24 Stockholm 2024
Multi-ancestry genome-wide association study of inflammatory bowel disease identifies 125 novel loci and directly implicates new genes in disease susceptibilityECCO'24 Stockholm 2024
Noninvasive assessment of gut function using transcriptional recording sentinel cellsECCO'24 Stockholm 2024